Clinical trial · Observational
AI for Onsite Cytology Evaluation in Endoscopic Ultrasound
Artificial Intelligence for Onsite Cytology Evaluation in Endoscopic Ultrasound
NCT07228689CI-TRIAL-00116345active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to determine if the widely available artificial intelligence platform ChatGPT can accurately identify the abnormalities present on cytology specimens obtained at EUS-FNB of solid mass lesions in the gastrointestinal tract, in comparison with interpretation by cytopathologists as the gold standard.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Neoplasm | Digestive System Neoplasm | ALIAS | 0.90 |
| Mass Lesion | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EUS-guided fine needle biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Interpretation of cytology specimen by cytopathologist onsite
- description
- The interpretation of the cytology specimens will be made onsite by the cytopathologist
- interventionNames
- Diagnostic Test: EUS-guided fine needle biopsy
- label
- Interpretation of cytology specimen by artificial intelligence
- description
- The interpretation of the cytology specimens will be made onsite by the AI program
- interventionNames
- Diagnostic Test: EUS-guided fine needle biopsy
Primary outcomes (1)
- measure
- Diagnostic adequacy at rapid onsite evaluation
- timeFrame
- 1 day
- description
- The ability of the AI systems to interpret specimen adequacy on cytology images
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years old or greater * Patients undergoing EUS-guided fine needle biopsy of solid mass lesions in the gastrointestinal tract Exclusion Criteria: * Age less than 18 years * Patients not undergoing sampling of solid mass lesions at EUS * Patients with cystic lesions in the gastrointestinal tract
References
Publications (0)
Data not yet available
No reference posted for this study.